Diagnosing Growth Hormone Deficiency: Can a Combined Arginine and Clonidine Stimulation Test Replace 2 Separate Tests?

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

This study aimed to assess the reliability and safety of a combined arginine-clonidine stimulation test (CACST).

The main outcome measures used to compare the tests were GH response (sufficiency/deficiency) and amplitude and timing of peak GH and safety parameters.

Who Took Part

According to the abstract, 515 children were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

During 2017-2019, 515 children aged >8 years underwent GH stimulation tests (CACST: n = 362 or clonidine stimulation test [CST]: n = 153).

How the Study Was Run

This was a retrospective, single-center, observational study.

What Was Measured

PubMed files the paper under topics including Arginine, Clonidine, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I and Reproducibility of Results.

The authors tagged it with the keywords GH deficiency, GH stimulation test and combined test.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 515 children.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.